The invention relates to novel liquid pharmaceutical compositions comprising at least one SGLT-2 inhibitor and one or more polar organic solvents, wherein the at least one SGLT-2 inhibitor comprises 1-cyano-2-(4- cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene according to formula (I): as well as corresponding processes of manufacturing such liquid pharmaceutical compositions and their medical uses.L'invention concerne de nouvelles compositions pharmaceutiques liquides comprenant au moins un inhibiteur de SGLT-2 et un ou plusieurs solvants organiques polaires, le ou les inhibiteur(s) de SGLT-2 comprenant 1-cyano-2-(4-cyclopropyl-benzyle)-4-(bêta-D-glucopyranos-1-yl)-benzène selon la formule (I) : ainsi que des procédés correspondants de fabrication de telles compositions pharmaceutiques liquides et leurs utilisations médicales.
